"目錄號: HY-14719
RO4987655(CH-4987655)是口服活性的MAP2K1/MEK1抑制劑跋核，IC50為5.2 nM薯酝，具有抗腫瘤活性母截。
相關產品
U0126-PD98059-Trametinib-Selumetinib-PD0325901-Cobimetinib-MEK162-Honokiol-CI-1040-OTS-964-Refametinib-AS703026-GDC-0623-BIX02189-Ro 5126766-
生物活性
Description
RO4987655(CH-4987655) is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1/MEK1 IC50=5.2 nM), with potential antineoplastic activity.IC50 value: 5.2 nMTarget: MEK1/2MEK inhibitor RO4987655 binds to and inhibits MEK, which may result in the inhibition of MEK-dependent cell signaling and the inhibition of tumor cell proliferation. MEK, a dual specificity threonine/tyrosine kinase, is a key component of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth; constitutive activation of this pathway has been implicated in many cancers.
Clinical Trial
Hoffmann-La Roche
Neoplasms
January 2009
Phase 1
View MoreCollapse
References
